SCHEMBL3687322

SCHEMBL3687322

CCCN(CCSc1ccc(OCC(=O)O)c(C)c1)S(=O)(=O)c1ccc(-c2cccc(F)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 14/20 0.46
PPARG P37231 2/20 0.46
PPARA Q07869 2/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.43
PTPN1 P18031 1/20 0.42
PTGER2 P43116 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3691055 0.92 PPARD (0.49) PPARDPPARGPPARAPTGDR2PTPN1
SCHEMBL3692840 0.92 PPARD (0.49) PPARDPPARGPPARAPTGDR2PTPN1
SCHEMBL3686980 0.90 PPARD (0.46) PPARDPPARGPPARAPTGDR2PTPN1
SCHEMBL3683309 0.90 PPARD (0.45) PPARDPTGDR2PTPN1
SCHEMBL3686823 0.90 PPARD (0.55) PPARDPPARGPPARAPTGDR2PTPN1
SCHEMBL3685273 0.88 PPARD (0.46) PPARDPPARGPPARAPTGDR2
SCHEMBL3692271 0.87 PPARD (0.49) PPARDPPARGPPARAPTGDR2PTPN1
SCHEMBL3691500 0.87 PPARD (0.49) PPARDPPARGPPARAPTGDR2PTPN1
SCHEMBL3680923 0.87 PTGDR2 (0.47) PPARDPPARGPPARAPTGDR2PTPN1
SCHEMBL3687327 0.86 PPARD (0.48) PPARDPPARGPPARAPTGDR2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP claimed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 US claimed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217433-A1 Sulfonamide derivatives as ppar modulators PPARD, PPARA, PPARG PPARD 1/4885PPARG 3/4885PPARA 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.